Do analysts prefer AADI or PBYI?

Puma Biotechnology has a consensus price target of $6.00, indicating a potential downside of 32.05%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Puma Biotechnology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend AADI or OCGN?

Ocugen has a consensus target price of $9.50, suggesting a potential upside of 603.70%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ocugen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has preferable valuation & earnings, AADI or OCGN?

Aadi Bioscience has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aadi Bioscience $25.07M 4.61 -$65.76M -$2.35 N/A Ocugen $4.41M 103.81 -$67.85M -$0.26 N/A

Is AADI or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Ocugen N/A -127,987.80% -115.95%

Do analysts recommend AADI or EPRX?

Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 167.86%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Do analysts prefer AADI or ABEO?

Abeona Therapeutics has a consensus price target of $19.33, indicating a potential upside of 222.76%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts recommend AADI or PRTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, AADI or PRTC?

Aadi Bioscience has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aadi Bioscience $25.07M 4.61 -$65.76M -$2.35 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Aadi Bioscience (AADI) Competitors

$4.68 -0.03 (-0.64%)

As of 08/13/2026

Compare

AADI vs. PBYI, OCGN, EPRX, ABEO, and PRTC

Should you buy Aadi Bioscience stock or one of its competitors? Aadi Bioscience's main competitors and comparable companies include Puma Biotechnology (PBYI), Ocugen (OCGN), Eupraxia Pharmaceuticals (EPRX), Abeona Therapeutics (ABEO), and PureTech Health (PRTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aadi Bioscience compare to Puma Biotechnology?

Aadi Bioscience (NASDAQ:AADI) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Puma Biotechnology has a consensus price target of $6.00, indicating a potential downside of 32.05%. Given Puma Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has a net margin of 11.50% compared to Aadi Bioscience's net margin of -246.06%. Puma Biotechnology's return on equity of 20.76% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Puma Biotechnology	11.50%	20.76%	13.22%

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Puma Biotechnology had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Puma Biotechnology and 0 mentions for Aadi Bioscience. Puma Biotechnology's average media sentiment score of 0.81 beat Aadi Bioscience's score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Puma Biotechnology	Positive

Puma Biotechnology has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.61	-$65.76M	-$2.35	N/A
Puma Biotechnology	$228.40M	2.00	$31.11M	$0.52	16.98

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Summary

Puma Biotechnology beats Aadi Bioscience on 13 of the 15 factors compared between the two stocks.

How does Aadi Bioscience compare to Ocugen?

Aadi Bioscience (NASDAQ:AADI) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ocugen has a consensus target price of $9.50, suggesting a potential upside of 603.70%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ocugen has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Ocugen	N/A	-127,987.80%	-115.95%

Aadi Bioscience has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.61	-$65.76M	-$2.35	N/A
Ocugen	$4.41M	103.81	-$67.85M	-$0.26	N/A

In the previous week, Ocugen had 25 more articles in the media than Aadi Bioscience. MarketBeat recorded 25 mentions for Ocugen and 0 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 beat Ocugen's score of -0.21 indicating that Aadi Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Ocugen	Neutral

Summary

Aadi Bioscience and Ocugen tied by winning 8 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Aadi Bioscience (NASDAQ:AADI) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Aadi Bioscience. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.61	-$65.76M	-$2.35	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Eupraxia Pharmaceuticals' return on equity of -63.97% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

In the previous week, Eupraxia Pharmaceuticals had 11 more articles in the media than Aadi Bioscience. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 0 mentions for Aadi Bioscience. Eupraxia Pharmaceuticals' average media sentiment score of 0.92 beat Aadi Bioscience's score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Eupraxia Pharmaceuticals	Positive

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 167.86%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Eupraxia Pharmaceuticals beats Aadi Bioscience on 12 of the 15 factors compared between the two stocks.

How does Aadi Bioscience compare to Abeona Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Abeona Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Abeona Therapeutics' return on equity of -39.69% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Abeona Therapeutics	N/A	-39.69%	-29.06%

In the previous week, Abeona Therapeutics had 11 more articles in the media than Aadi Bioscience. MarketBeat recorded 11 mentions for Abeona Therapeutics and 0 mentions for Aadi Bioscience. Abeona Therapeutics' average media sentiment score of 0.08 beat Aadi Bioscience's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Abeona Therapeutics	Neutral

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Abeona Therapeutics has a consensus price target of $19.33, indicating a potential upside of 222.76%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Abeona Therapeutics has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.61	-$65.76M	-$2.35	N/A
Abeona Therapeutics	$5.82M	58.65	$71.18M	$0.97	6.18

Summary

Abeona Therapeutics beats Aadi Bioscience on 13 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to PureTech Health?

Aadi Bioscience (NASDAQ:AADI) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
PureTech Health	Neutral

PureTech Health has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. PureTech Health's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
PureTech Health	N/A	N/A	N/A

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Aadi Bioscience has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.61	-$65.76M	-$2.35	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Summary

PureTech Health beats Aadi Bioscience on 6 of the 10 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$115.58M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.05	6.29	211.09	21.74
Price / Sales	4.61	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.09	16.78	12.91	6.24
Net Income	-$65.76M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-0.43%	1.74%	1.12%	1.07%
1 Month Performance	21.88%	1.60%	1.79%	1.03%
1 Year Performance	173.68%	56.43%	67.69%	20.77%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$4.68 -0.6%	N/A	+175.4%	$115.58M	$25.07M	N/A	40
PBYI Puma Biotechnology	1.2456 of 5 stars	$8.77 +0.9%	$6.00 -31.6%	+64.3%	$448.58M	$228.40M	16.87	200
OCGN Ocugen	1.8027 of 5 stars	$1.37 +4.6%	$9.50 +593.4%	+31.1%	$444.23M	$4.58M	N/A	80	Analyst Upgrade Analyst Revision
EPRX Eupraxia Pharmaceuticals	2.4232 of 5 stars	$6.70 +0.6%	$18.00 +168.7%	+22.4%	$433.03M	N/A	N/A	29	News Coverage Earnings Report
ABEO Abeona Therapeutics	3.1667 of 5 stars	$7.40 -0.7%	$19.00 +156.8%	-3.4%	$424.61M	$14.54M	7.63	90	Trending News Earnings Report Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. PBYI, OCGN, EPRX, ABEO, and PRTC

How does Aadi Bioscience compare to Puma Biotechnology?

Summary

How does Aadi Bioscience compare to Ocugen?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Summary

How does Aadi Bioscience compare to Abeona Therapeutics?

Summary

How does Aadi Bioscience compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. PBYI, OCGN, EPRX, ABEO, and PRTC

How does Aadi Bioscience compare to Puma Biotechnology?

Do analysts prefer AADI or PBYI?

Is AADI or PBYI more profitable?

Do institutionals & insiders have more ownership in AADI or PBYI?

Does the media refer more to AADI or PBYI?

Which has better valuation and earnings, AADI or PBYI?

Which has more volatility & risk, AADI or PBYI?

Summary

How does Aadi Bioscience compare to Ocugen?

Which has more volatility and risk, AADI or OCGN?

Do institutionals & insiders hold more shares of AADI or OCGN?

Do analysts recommend AADI or OCGN?

Is AADI or OCGN more profitable?

Which has preferable valuation & earnings, AADI or OCGN?

Does the media refer more to AADI or OCGN?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Which has higher earnings and valuation, AADI or EPRX?

Do institutionals & insiders believe in AADI or EPRX?

Is AADI or EPRX more profitable?

Does the media prefer AADI or EPRX?

Which has more risk and volatility, AADI or EPRX?

Do analysts recommend AADI or EPRX?

Summary

How does Aadi Bioscience compare to Abeona Therapeutics?

Is AADI or ABEO more profitable?

Does the media refer more to AADI or ABEO?

Which has more volatility & risk, AADI or ABEO?

Do analysts prefer AADI or ABEO?

Do institutionals & insiders believe in AADI or ABEO?

Which has preferable earnings & valuation, AADI or ABEO?

Summary

How does Aadi Bioscience compare to PureTech Health?

Do analysts recommend AADI or PRTC?

Do institutionals and insiders hold more shares of AADI or PRTC?

Does the media prefer AADI or PRTC?

Is AADI or PRTC more profitable?

Which has more volatility & risk, AADI or PRTC?

Which has better earnings and valuation, AADI or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools